Lisata Therapeutics, Inc.
LSTA
$2.26
$0.17568.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.93% | -9.03% | -19.18% | -12.44% | -8.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.94% | -10.44% | -12.59% | -7.17% | -5.51% |
| Operating Income | 12.83% | 10.44% | 12.59% | 7.17% | 5.51% |
| Income Before Tax | 10.30% | 9.49% | 60.89% | 58.74% | 59.14% |
| Income Tax Expenses | 65.75% | 65.75% | 65.75% | -- | 6.01% |
| Earnings from Continuing Operations | 4.10% | 3.38% | 60.68% | 64.31% | 61.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.10% | 3.38% | 60.68% | 64.31% | 61.57% |
| EBIT | 12.83% | 10.44% | 12.59% | 7.17% | 5.51% |
| EBITDA | 12.87% | 10.48% | 12.79% | 7.48% | 5.97% |
| EPS Basic | 7.05% | 6.53% | 74.14% | 77.76% | 77.20% |
| Normalized Basic EPS | 13.42% | 11.99% | 29.70% | 38.56% | 47.45% |
| EPS Diluted | 6.93% | 6.47% | 74.13% | 77.77% | 77.22% |
| Normalized Diluted EPS | 13.42% | 11.99% | 29.70% | 38.56% | 47.45% |
| Average Basic Shares Outstanding | 3.18% | 3.30% | 14.92% | 32.35% | 56.15% |
| Average Diluted Shares Outstanding | 3.18% | 3.30% | 14.92% | 32.35% | 56.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |